Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | HSPA9 | P38646 | 5/20 | 0.62 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.51 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MYOC | Q99972 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750747 | 0.90 | HSPA9 (0.63) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL21750809 | 0.81 | RARA (0.47) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL21750775 | 0.79 | EPHX2 (0.54) | MEN1KMT2AMAPTSMN1; SMN2HSPA9 | |
| SCHEMBL21750666 | 0.78 | MEN1 (0.54) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL21750659 | 0.77 | HSPA9 (1.00) | MEN1KMT2AMAPTRAB9ANPC1 | |
| Iodide SCHEMBL21750676 | 0.76 | HSPA9 (1.00) | MEN1KMT2AMAPTRAB9ANPC1 | |
| Iodide SCHEMBL31010405 | 0.76 | HSPA9 (1.00) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL8459297 | 0.74 | RARA (0.69) | MEN1KMT2ARAB9ANPC1MAPK1 | |
| SCHEMBL21750785 | 0.73 | MEN1 (0.54) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL6302157 | 0.73 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-03-16 | — | — | US | claimed |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-06-03 | — | — | US | disclosed |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163415-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | MEN1 2784/4885KMT2A 1349/4885MAPT 4035/4885 |
| US-10947198-B2 | Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, XPOT | MEN1 2784/4885KMT2A 1349/4885MAPT 4035/4885 |
| US-11993573-B2 | Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents | HCCS, CDYL, CDYL2 | MEN1 2252/4885KMT2A 973/4885MAPT 4052/4885 |
| US-20200062711-A1 | CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS | HCCS, CDYL, XPOT | MEN1 2784/4885KMT2A 1349/4885MAPT 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.